Literature DB >> 19633599

Skin barrier breakdown: a renaissance in emollient therapy.

Michael J Cork1, Simon Danby.   

Abstract

Breakdown of the skin barrier is the first event in the development of atopic eczema (atopic dermatitis). Research over the past five years has indicated that this arises as a result of the interaction of environmental agents such as soap and other detergents with the products of changes in several genes. These genetic changes predispose to the breakdown of the skin barrier, which allows the penetration of allergens, triggering a flare of atopic eczema. This new understanding of how breakdown of the skin barrier is the first event in the development of atopic eczema provides a rationale for a renaissance in the use of a complete emollient therapy regimen in atopic eczema and related skin barrier breakdown diseases, such as asteatotic eczema and irritant contact dermatitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19633599     DOI: 10.12968/bjon.2009.18.14.43356

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  13 in total

1.  Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings.

Authors:  Fiona Cowdell; Yuri T Jadotte; Steven J Ersser; Simon Danby; Sandra Lawton; Amanda Roberts; Judith Dyson
Journal:  Cochrane Database Syst Rev       Date:  2020-01-23

Review 2.  Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies.

Authors:  Ivette A G Deckers; Susannah McLean; Sanne Linssen; Monique Mommers; C P van Schayck; Aziz Sheikh
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

3.  Emollient efficacy and acceptability in the treatment of eczematous dry skin: A double-blind, randomised comparison of two UK-marketed products.

Authors:  Jasmina Djokic-Gallagher; Philip Rosher; Jennine Walker; Krystyna Sykes; Valerie Hart
Journal:  J Dermatolog Treat       Date:  2016-02-10       Impact factor: 3.359

4.  Development and Study of Semi-Solid Preparations Containing the Model Substance Corticotropin (ACTH): Convenience Application in Neurodegenerative Diseases.

Authors:  Wioletta Siemiradzka; Barbara Dolińska; Florian Ryszka
Journal:  Molecules       Date:  2020-04-16       Impact factor: 4.411

5.  Parents' experience of childhood atopic eczema in the public health sector of Gauteng.

Authors:  Kaarina F Meintjes; Ann G W Nolte
Journal:  Curationis       Date:  2015-04-29

6.  Effectiveness of a skin care programme for the prevention of contact dermatitis in healthcare workers (the Healthy Hands Project): A single-centre, cluster randomized controlled trial.

Authors:  Maryam Soltanipoor; Sanja Kezic; Judith K Sluiter; Fleur de Wit; Angela L Bosma; Ruth van Asperen; Thomas Rustemeyer
Journal:  Contact Dermatitis       Date:  2019-03-15       Impact factor: 6.600

7.  Objective and subjective in vivo comparison of two emollient products.

Authors:  Jasmina Djokic-Gallagher; Phil Rosher; Jennine Walker; Valerie Hart
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-08-08

8.  N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients.

Authors:  Chao Yuan; Xue-Min Wang; Alexandre Guichard; Yi-Mei Tan; Chun-Yan Qian; Li-Jie Yang; Philippe Humbert
Journal:  Clin Interv Aging       Date:  2014-07-17       Impact factor: 4.458

9.  Knowledge, instruction and behavioural change: building a framework for effective eczema education in clinical practice.

Authors:  Deryn Lee Thompson; Murray John Thompson
Journal:  J Adv Nurs       Date:  2014-04-30       Impact factor: 3.187

10.  A Double-Blind, Randomised Study Comparing the Skin Hydration and Acceptability of Two Emollient Products in Atopic Eczema Patients with Dry Skin.

Authors:  Jasmina Djokic-Gallagher; Phil Rosher; Gabriela Oliveira; Jennine Walker
Journal:  Dermatol Ther (Heidelb)       Date:  2017-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.